Mode
Text Size
Log in / Sign up

Chikungunya seroprevalence was 34.3% overall, significantly higher in urban Colombo communities compared to semi-urban areas.

Chikungunya seroprevalence was 34.3% overall, significantly higher in urban Colombo communities comp…
Photo by Francis Tokede / Unsplash
Key Takeaway
Note higher chikungunya seroprevalence in urban Colombo settings prior to the 2024 outbreak, suggesting environmental drivers of transmission.

This observational cohort study evaluated the seroprevalence of chikungunya virus infection among 1,196 participants residing in urban and semi-urban communities within Colombo, Sri Lanka, between September and November 2024. The primary outcome measured was age-stratified seroprevalence of chikungunya-specific IgG antibodies, reflecting past exposure rather than active infection. The study population included 816 residents from urban areas and 380 from semi-urban communities.

Overall chikungunya IgG seropositivity was 34.3% (410 of 1,196 participants). Seroprevalence was significantly higher in urban populations (39.6%) compared to semi-urban populations (22.9%), with an adjusted odds ratio of 7.48 (95% CI 4.05 to 13.81; p<0.001) for living in an urban area. Conversely, the use of mosquito nets was associated with a reduced risk of seropositivity, with an adjusted odds ratio of 0.50 (95% CI 0.27 to 0.93; p=0.029). Seroprevalence in individuals aged under 16 years was minimal at 0.55%.

No adverse events, discontinuations, or data on tolerability were reported, as this was a serological survey rather than an interventional trial. Key limitations include the observational nature of the study, which precludes causal inference regarding environmental or behavioral factors. Additionally, the study was conducted prior to the 2024 outbreak, meaning seroprevalence reflects historical exposure rather than current infection status. Generalizability beyond Colombo, Sri Lanka, is uncertain. These results highlight the potential role of population density and housing conditions in transmission dynamics.

Study Details

Study typeCohort
Sample sizen = 816
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Introduction: Following a large chikungunya outbreak during 2006 to 2008, Sri Lanka did not report any outbreaks for a 16 year period until end of 2008, possibly due to population immunity. Therefore, understanding baseline immunity prior to outbreaks is crucial to inform implementation of vaccine strategies. Methods: We assessed the age stratified seroprevalence for chikungunya in an urban (n=816) and a semi urban (n=380) community in Colombo, Sri Lanka, from September to November 2024, prior to the commencement of the large chikungunya outbreak, in December 2024. Sociodemographic, socioeconomic and clinical data were collected and chikungunya specific IgG measured in serum samples. Results: Of 1196 participants, 410 (34.3%) were chikungunya IgG seropositive. Seroprevalence was significantly higher in urban populations compared with semi urban populations (39.6% vs 22.9%; p<0.001) and increased significantly with age in urban areas but not in semi-urban areas. Living in an urban area was the strongest independent risk factor of chikungunya seropositivity (aOR 7.48, 95% CI 4.05 to 13.81; p<0.001), consistent with the higher population density, poor housing conditions and overcrowding observed in that setting. The use of mosquito nets was independently associated with reduced risk of seropositivity (aOR 0.50, 95% CI 0.27 to 0.93; p=0.029). Almost no individuals aged <16 years had evidence of prior infection (0.55%), indicating minimal transmission in the preceding 16 years. In the urban cohort, seropositivity was significantly associated with diabetes, central obesity, overweight, and hypertension. Conclusions: There appears to have been minimal chikungunya transmission in the 16 years preceding the 2024 outbreak, with a large population susceptible to chikungunya. Higher seroprevalence in urban populations highlights the role of population density, overcrowding, and housing conditions as key drivers of transmission.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.